Did the MPLT CSO have any recent share acquisitions mentioned?

Yes. A footnote notes that her holdings include 808 shares acquired under MapLight Therapeutics’ stock purchase plan on March 31, 2026. This detail clarifies that her direct ownership reflects both purchase plan acquisitions and subsequent tax-related share sales.

MapLight Therapeutics (MPLT) CSO sells 4,513 shares to cover taxes

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

MapLight Therapeutics Chief Scientific Officer Lillie James Woodruff sold 4,513 shares of Voting Common Stock primarily to cover tax obligations from vested restricted stock units. The sales occurred on April 15–16, 2026 at weighted average prices around $26–27 per share.

After these transactions, she directly holds 295,157 shares. A footnote explains that the shares sold represent the number required to satisfy statutory tax withholding tied to RSU vesting, indicating a compensation-related, rather than purely discretionary, reduction in her holdings.

Insider Trade Summary

Net Seller: 4,513 shares ($122,574)

Net Sell 3 txns

Insider Lillie James Woodruff

Role Chief Scientific Officer

Sold 4,513 shs ($123K)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock	686	$27.01	$19K
Sale	Voting Common Stock	2,097	$27.49	$58K
Sale	Voting Common Stock	1,730	$26.82	$46K

Holdings After Transaction: Voting Common Stock — 297,254 shares (Direct)

Footnotes (1)

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.33 to $27.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5). Includes 808 shares acquired under the Issuer's stock purchase plan on March 31, 2026. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2201 to $27.2197 inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $27.9898 inclusive.

Key Figures

Shares sold: 4,513 shares Post-transaction holdings: 295,157 shares Sale price April 15: $26.82 per share +3 more

6 metrics

Shares sold 4,513 shares Total Voting Common Stock sold on April 15–16, 2026

Post-transaction holdings 295,157 shares Voting Common Stock held directly after April 16, 2026

Sale price April 15 $26.82 per share 1,730 shares sold as weighted average price

Sale price April 16 (lot 1) $27.01 per share 686 shares sold as weighted average price

Sale price April 16 (lot 2) $27.49 per share 2,097 shares sold as weighted average price

Employee stock purchase 808 shares Shares acquired under stock purchase plan on March 31, 2026

Key Terms

restricted stock units, statutory tax withholding obligations, weighted average price, stock purchase plan

4 terms

restricted stock units financial

"in connection with the vesting of the restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

statutory tax withholding obligations financial

"shares required to be sold to cover the statutory tax withholding obligations"

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

stock purchase plan financial

"Includes 808 shares acquired under the Issuer's stock purchase plan on March 31, 2026."

Form 4 Insider Transactions: What Each Field Means →

04/17/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lillie James Woodruff

(Last)

(First)

(Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	04/15/2026		S		1,730⁽¹⁾	D	$26.82⁽²⁾	297,940⁽³⁾	D
Voting Common Stock	04/16/2026		S		686⁽¹⁾	D	$27.01⁽⁴⁾	297,254	D
Voting Common Stock	04/16/2026		S		2,097⁽¹⁾	D	$27.49⁽⁵⁾	295,157	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.33 to $27.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5).

3. Includes 808 shares acquired under the Issuer's stock purchase plan on March 31, 2026.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2201 to $27.2197 inclusive.

5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $27.9898 inclusive.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MPLT Chief Scientific Officer report?

Chief Scientific Officer Lillie James Woodruff reported selling 4,513 shares of MapLight Therapeutics Voting Common Stock. These transactions on April 15–16, 2026 were linked to covering statutory tax withholding obligations arising from the vesting of restricted stock units.

At what prices did the MPLT CSO sell shares in this Form 4?

The reported sales occurred at weighted average prices around $26–27 per share. Individual transactions included 1,730 shares at $26.82, 686 shares at $27.01, and 2,097 shares at $27.49, with additional disclosure that trades spanned specified intraday price ranges.

How many MPLT shares does the CSO hold after the reported sales?

Following the reported transactions, Lillie James Woodruff directly holds 295,157 shares of MapLight Therapeutics Voting Common Stock. This figure reflects her position after selling 4,513 shares associated with statutory tax withholding on vested restricted stock units.

Why were MPLT shares sold by the Chief Scientific Officer?

A footnote states the reported sales represent the number of shares required to be sold to cover statutory tax withholding obligations. These obligations arose in connection with the vesting of restricted stock units granted to the Chief Scientific Officer as part of her compensation.

How many MPLT shares did the CSO sell on each reported date?

On April 15, 2026, Lillie James Woodruff sold 1,730 shares at a weighted average price of $26.82. On April 16, 2026, she sold 686 shares at $27.01 and 2,097 shares at $27.49, totaling 4,513 shares sold over the two days.